Hobson Prior’s Post

𝐂𝐞𝐥𝐥𝐞𝐜𝐭𝐢𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 Cellectis Cellectis has entered into a collaboration with AstraZeneca AstraZeneca, aiming to accelerate next-gen therapeutics in oncology, immunology, and rare diseases. Under this partnership: AstraZeneca will use Cellectis' gene editing tech and manufacturing capabilities to design novel cell and gene therapy candidates. 25 genetic targets are reserved for AstraZeneca, with the potential for up to 10 candidate products. Cellectis receives an upfront payment of $25M and is eligible for milestone payments up to $220M for each of the 10 candidate products. AstraZeneca makes an initial equity investment of $80M in Cellectis, with the option for a further $140M investment. Cellectis will use the funds for gene editing tools and R&D expenses. André Choulika Andre Choulika Ph.D., CEO of Cellectis, said this partnership will advance innovative medicines. Marc Dunoyer, AstraZeneca's Chief Strategy Officer, believes this collaboration complements their expertise in cell therapy and genomic medicine. This deal doesn't require a public offering. #collaboration #medicine #celltherapy #genomicmedicine #investment #genetherapy #therapeutics #oncology

DPU Pharmacy successfully set the stage rolling with the inaugural session of the 4th international faculty development program (4th iFDP) on Emerging Trends in Oncology: Therapeutics and Diagnostics , on 23rd March 2024. Dr. Vikram Gota, Professor, Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Chief Guest and Keynote speaker enlightened the delegates who had gathered from various institutions across the country through the virtual platform on the Readiness for Gene and cell-based therapies in India. The session delved into the transformative potential of gene and cell therapies, shedding light on their mechanisms, targeted diseases, and the global landscape. Dr. Gota detailed the approaches for gene and cell therapy, highlighting the innovative techniques used to tackle genetic disorders and cancer. The discussion transitioned into the Indian scenario, comparing it with global standards and exploring India's capacity and readiness to adopt these advanced treatments. Through a SWOT analysis, Dr. Gota outlined the strengths, such as India's robust biotech research base, and weaknesses, including regulatory hurdles. The session set the stage for meaningful deliberations in Oncology research. Join us for the, Second session on 30 March 2024. #dpu#oncology#gene therapy#CAR-T

🚨 𝐂𝐆𝐓 𝐍𝐞𝐰𝐬: 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬! The FDA is 𝒐𝒏𝒆 𝒔𝒕𝒆𝒑 𝒄𝒍𝒐𝒔𝒆𝒓 to approving the first gene-editing therapy, "exa-cel," which utilises CRISPR to treat sickle cell disease. The FDA is set to make a decision on 𝘊𝘙𝘐𝘚𝘗𝘙 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴 and 𝘝𝘦𝘳𝘵𝘦𝘹's therapy by December 8th. Five IND applications were also cleared by the FDA in October. 𝘊𝘦𝘭𝘭 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘩𝘢𝘥 𝘴𝘰𝘮𝘦 𝘪𝘯𝘵𝘳𝘪𝘨𝘶𝘪𝘯𝘨 𝘢𝘤𝘲𝘶𝘪𝘴𝘪𝘵𝘰𝘯𝘴 with Europe seeing Alaya.bio acquiring ALL assets from Ixaka France + Clade Therapeutics boosting their solid tumour pipeline with fully integrating 𝐆𝐚𝐝𝐞𝐭𝐚 𝐁.𝐕. ➡️ 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐚𝐥𝐬𝐨 𝐰𝐞𝐫𝐞 𝐚 𝐬𝐭𝐫𝐨𝐧𝐠 𝐭𝐡𝐞𝐦𝐞 for October as shown through SpliceBio x Spark Therapeutics, Inc. in gene therapy as well as Cellipont Bioservices x Diakonos Oncology for cell therapy and cancer vaccines. Special October mention goes to Bryan Kobel and TC BioPharm as in October they submitted their first IND for AML + formed an exciting CDMO partnership with Excellos providing a scaling up US clinical trial solution. #celltherapy #genetherapy #biotechnology #CGTweekly

DPU Pharmacy successfully set the stage rolling with the inaugural session of the 4th international faculty development program (4th iFDP) on Emerging Trends in Oncology: Therapeutics and Diagnostics , on 23rd March 2024. Dr. Vikram Gota, Professor, Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Chief Guest and Keynote speaker enlightened the delegates who had gathered from various institutions across the country through the virtual platform on the Readiness for Gene and cell-based therapies in India. The session delved into the transformative potential of gene and cell therapies, shedding light on their mechanisms, targeted diseases, and the global landscape. Dr. Gota detailed the approaches for gene and cell therapy, highlighting the innovative techniques used to tackle genetic disorders and cancer. The discussion transitioned into the Indian scenario, comparing it with global standards and exploring India's capacity and readiness to adopt these advanced treatments. Through a SWOT analysis, Dr. Gota outlined the strengths, such as India's robust biotech research base, and weaknesses, including regulatory hurdles. The session set the stage for meaningful deliberations in Oncology research. Join us for the, Second session on 30 March 2024. #dpu#oncology#gene therapy#CAR-T

Our CMO Jens Bjørheim is quoted in the Scrip article about "What Does 2024 Hold for Biopharma? Part 4: Transformative Technology": #biotech #cancerresearch #cancervaccine #2024outlook https://lnkd.in/dWeM2Bcy (subscribers only) "Jens Bjørheim, Chief Medical Officer at Ultimovacs ASA, was optimistic about progress in cancer vaccines, meanwhile: “In recent years, there has been remarkable innovation and advances in the development of therapeutic cancer vaccines. New technologies are showing highly promising results in clinical studies. I believe this positive trend will continue throughout 2024 and in the years ahead. By training the immune system to target cancer-associated antigens and tumor antigens, we believe the vaccine approach could benefit more patients across tumor types. While many vaccines are tailor-made using neoantigens from the patient’s tumor, a more universal approach is a complementary strategy in the emerging cancer vaccine landscape. Off-the-shelf vaccines that don’t require sophisticated hospital infrastructure hold the potential to enhance applicability and impact a larger population of patients, including rural and underserved communities.”

Astellas has added another program to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumors. The Japanese pharma is paying $50 million upfront for an option on P-MUC1C-ALLO1, an allogeneic CAR-T still in early-stage clinical development, which includes $25 million to buy an 8.8% stake in San Diego-based Poseida. It also gets an observer seat on the US biotech's board and a say in any change in control of the company. The deal is a fillip for Poseida, still dealing with the loss of a wide-ranging alliance with Takeda in June focused on the development of up to eight gene therapies, which was agreed in 2021 with a potential value of around $3.6 billion if all objectives were met. Want to know more about the biotech revolution? Join us for the International conference on Biotechnology 2023. Website: https://lnkd.in/gjHdmmtD #biotechnology #biotechnologyindustry #biodiversity #genetics #geneticengineering #genomics #stemcelltherapy #microbiology #fermentation #cancer #researchers #researchinnovation #bioinformatics #proteinengineering #callforpapers #callforspeakers #callforabstracts #registernow #biotechnologyconference2023

The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years. -The FDA’s Center for Biologic Evaluation and Research (CBER) approved a large number of cell and gene therapies, vaccines and blood products in 2023. This included the first CRISPR–Cas9-based gene editing product, two vaccines for respiratory syncytial virus (RSV) and a burst of gene therapies. - By therapeutic area, oncology continues to accumulate the most approvals. CDER gave a green light to 13 (24%) new cancer therapies in 2023. - By modality, the medical toolbox continues to get more diverse. 2023 saw an increase in the number of nucleotide-based therapeutics, including a second RNA-aptamer product. On the antibody front, 4 T-cell engaging bispecifics arrived. #oncology #treatmentoptions #fdaapproval More info: https://lnkd.in/dwkUMyQy

The reality of today’s precision medicine is only 10% of cancer patients experience a clinical benefit from treatments matched to tumor DNA mutations (via biomarker testing). OncoDxRx's mission is to build a personalized guide of the most effective drugs for every cancer patient. OncoDxRx’s one-of-a-kind PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) works by testing tumor gene activities from a patient’s own blood before administering treatment, tailoring therapies that are most likely to benefit the patient while minimizing waiting time, cost and ineffective drugs. Other than DNA mutations, PGA takes a different approach to personalizing treatments. The technology takes a sample of a patient’s blood, analyzes patient-unique gene expression signature, searches and maps over 700 drugs (approved, investigational or in clinical trials). In this process, the scientists look for the medications that the patient has a high likelihood to respond to. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Based on the study “Complementarity-determining region clustering may cause CAR-T cell dysfunction” published in nature communications. The researcher chose five scFv molecules from A to E by phage display panning based on specific binding to human IL13Rα2 but not the more abundantly shown IL13Rα1 and The result reported   - CAR-T Cells are a promising way to reduce tumor cell responsiveness and enhance cell survival. - CAR - T Cell has confirmed to mediate in CDR loops. - Interestingly, it can kill IL13Rα2-expressing glioblastoma cells effectively.  - scFv demonstrated their challenges about forecast because of  CAR clustering.  - Interaction between CDR loops also impacts CAR stability and functionality. It is another step of CAR - T cell study that enables new perspective, understanding and challenge to adapt the future and Atlantis Bioscience believes that we will give new shed or chapter of cell and gene therapeutics, treating cancer to help many patients lives better across the world with translational study and solution. Atlantis Bioscience is ready to support all range of researchers and scientist, to leverage their study to make a difference in life with cutting edge, easy to use,  efficient,  time saving and quality  solutions. Explore our solution, who we are and more via our website or LinkedIn    Reference : https://lnkd.in/gqP3DY2R #Atlantis #BenchtoBed #DiscoverSolutions #AtlantisBioscience #Celltherapies #Geneticengineering #Immunotherapy #Tcellreceptor #Cancer #Cancertherapy #Cellandgenetherapy #Cartcell #Toxicity #Cell #Antigen #Cell

$100m in funding secured, New M&A & CAR-T approval, Here's this week's news in CGT 👇 🚨 Today, Paris-based gene therapy biotech company, Vivet Therapeutics, successfully secured EUR 4.9 million in private funding through the support of Bpifrance. 2. Adicet Bio, Inc. received a significant $98 million boost through a public follow-on offering, strengthening their commitment to advancing allogeneic gamma delta T cell therapies for autoimmune + cancer. ➡️ Regeneron bets on cell therapy, leading to a fantastic outcome for 150 talented individuals as they transition into exciting new roles within the Regeneron family. Regeneron has formed 𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐨𝐧 𝐂𝐞𝐥𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 through an agreement with 2seventy bio, acquiring full rights to its immune cell therapy pipeline. ✅ FDA has approved a new manufacturing process for Kite Pharma's Yescarta CAR T-cell therapy, reducing the median turnaround time from 16 to 14 days. This change streamlines the production of personalized cell therapy, crucial for patients with aggressive large B-cell lymphoma. The quicker delivery 𝐚𝐢𝐦𝐬 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬' 𝐜𝐡𝐚𝐧𝐜𝐞𝐬 𝐨𝐟 𝐬𝐮𝐫𝐯𝐢𝐯𝐚𝐥, as Yescarta has shown superior overall survival compared to standard care as a second-line treatment for these cases. 🔥 Partnerships are forming every week as Umoja Biopharma strikes a THIRD strategic collab in THREE weeks, this time with AbbVie to create innovative in-situ CAR-T cell therapies, utilising Umoja's VivoVecTM gene delivery platform and leveraging AbbVie's oncology expertise. 𝘊𝘶𝘳𝘪𝘰𝘶𝘴 𝘵𝘰 𝘴𝘦𝘦 𝘞𝘏𝘖 𝘦𝘭𝘴𝘦 𝘮𝘢𝘥𝘦 𝘮𝘰𝘷𝘦𝘴 𝘵𝘩𝘪𝘴 𝘸𝘦𝘦𝘬? Sign up for FREE to my 𝐂𝐆𝐓𝐰𝐞𝐞𝐤𝐥𝐲 newsletter and discover the newest breakthroughs and advancements, here: https://lnkd.in/etZK5kzZ #celltherapy #genetherapy #biotech #CGTweekly